BPCA Adverse Event Reports To Be Presented According To Three-Tier System
FDA has developed a three-tier system for its presentations of pediatric drug adverse event reports to its Pediatric Advisory Committee, as mandated by the Best Pharmaceuticals for Children Act
You may also be interested in...
FDA should consider posting concerns about psychiatric and cardiovascular adverse events with Johnson & Johnson's Concerta and other methylphenidate products on the agency's upcoming "Drug Watch" website, members of FDA's Pediatric Advisory Committee said
Ortho-McNeil is changing labeling for Ortho Tri-Cyclen to include information from its pediatric exclusivity study showing lack of significant effect on low mineral bone density in anorexic adolescent females
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011